Combined targeting of MEK and mTOR has been successfully applied in several preclinical cancer model systems, leading to potential opportunities to overcome some forms of acquired drug resistance in liver and pancreatic cancers (23, 24). The gene discussed is MAP2K7; the disease is cancer.